spinal muscular atrophy

Spinraza launch set for blockbuster trajectory
Spinraza launch set for blockbuster trajectory
BioPharma Dive
Spinraza
Biogen
SMA
spinal muscular atrophy
Flag link:
For Biogen's Spinraza launch, things are looking up on the coverage front: analyst
For Biogen's Spinraza launch, things are looking up on the coverage front: analyst
Fierce Pharma
Biogen
Spinraza
drug launches
spinal muscular atrophy
SMA
Flag link:
PTC and Roche report solid data for Spinraza rival
PTC and Roche report solid data for Spinraza rival
BioPharma Dive
PTC Therapeutics
Roche
Spinraza
Biogen
RG7916
SMA
spinal muscular atrophy
Flag link:
Biogen’s Spinraza Witnessed Robust Patient Demand in 1Q17
Biogen’s Spinraza Witnessed Robust Patient Demand in 1Q17
Market Realist
Biogen
Spinraza
patients
SMA
spinal muscular atrophy
Flag link:
​Hyde Park boy with rare disease wins appeal, will receive Biogen drug
​Hyde Park boy with rare disease wins appeal, will receive Biogen drug
Bizjournals.com
Biogen
Spinraza
SMA
spinal muscular atrophy
Flag link:
Biogen touts stronger-than-expected rollout for Spinraza
Biogen touts stronger-than-expected rollout for Spinraza
BioPharma Dive
Biogen
Spinraza
drug launches
SMA
spinal muscular atrophy
Flag link:
Did Biogen Inc. Shoot Itself in the Foot?
Did Biogen Inc. Shoot Itself in the Foot?
Motley Fool
Biogen
drug pricing
Spinraza
SMA
spinal muscular atrophy
Flag link:
Another US insurer places limits on Spinraza coverage
Another US insurer places limits on Spinraza coverage
BioPharma Dive
Biogen
Spinraza
spinal muscular atrophy
insurers
Humana
Flag link:
Biogen's latest drug may be costly, but new data suggests it saves lives
Biogen's latest drug may be costly, but new data suggests it saves lives
Bizjournals.com
Biogen
Spinraza
SMA
spinal muscular atrophy
Flag link:
Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk
Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk
Endpoints
Biogen
Spinraza
SMA
spinal muscular atrophy
Flag link:
New drug price controversy looms as Biogen stuns payers with Spinraza’s $750K sticker — analyst
New drug price controversy looms as Biogen stuns payers with Spinraza’s $750K sticker — analyst
Endpoints
Biogen
Spinraza
drug pricing
spinal muscular atrophy
Flag link:
The FDA's Christmas Breakthrough
The FDA's Christmas Breakthrough
Forbes
FDA
Biogen
spinal muscular atrophy
Spinraza
Nusinersen
Flag link:
Poised to launch a new drug for SMA, Biogen and Ionis shares jump on more promising PhIII data
Poised to launch a new drug for SMA, Biogen and Ionis shares jump on more promising PhIII data
Endpoints
Biogen
Ionis
spinal muscular atrophy
Nusinersen
Flag link:
Biogen Submits NDA for SMA Drug (BIIB, IONS)
Biogen Submits NDA for SMA Drug (BIIB, IONS)
Investopedia
Biogen
SMA
spinal muscular atrophy
Ionis Pharmaceuticals
Nusinersen
Flag link:
Biogen, Ionis Rise as Muscle Drug Hits Goal in Late-Stage Trial
Biogen, Ionis Rise as Muscle Drug Hits Goal in Late-Stage Trial
Bloomberg
Biogen
Ionis
clinical trials
Nusinersen
spinal muscular atrophy
Flag link:
Will Ionis And Biogen Get An Early Approval For Nusinersen?
Will Ionis And Biogen Get An Early Approval For Nusinersen?
Seeking Alpha
Biogen
Ionis
Nusinersen
spinal muscular atrophy
Flag link:
Biogen pressed for more accessible medicines
Biogen pressed for more accessible medicines
Boston Globe, MA
Biogen
patients
spinal muscular atrophy
Flag link:
Infants with rare cases of SMA get stronger, live longer on Isis drug
Infants with rare cases of SMA get stronger, live longer on Isis drug
Fierce Biotech
SMA
spinal muscular atrophy
Isis Pharmaceuticals
ISIS-SMNRx
Flag link:
Roche presses pause on PTC's SMA drug over a safety scare
Roche presses pause on PTC's SMA drug over a safety scare
Fierce Biotech
Roche
PTC Therapeutics
spinal muscular atrophy
RG7800
Flag link:
Pfizer backs out of development deal with Repligen
Pfizer backs out of development deal with Repligen
Seeking Alpha
Pfizer
Repligen
SMA
spinal muscular atrophy
Flag link: